Research: Innovative treatment reduces 21% mortality of heart failure patients Israel today

For the first time treatment was able to reduce by 21% mortality and hospitalizations in heart failure patients with left ventricular contractile disorder.

It is a type of heart injury for which there has been no drug treatment so far and about half of those suffering from heart failure suffer from it.

The results of the study, which is defined by doctors as noisy, were presented last weekend at a conference of the European Society of Cardiology (ESC).

The study found that treatment with the drug Jardians (a drug registered in Israel for the treatment of diabetes), showed an unprecedented 21% reduction in the risk of mortality due to cardiovascular disease and hospitalization as a result of heart failure.

There was also a 27% decrease in overall hospitalizations due to heart failure.

This is the first study in 18 years that shows positive results for 30 million people worldwide (and in Israel about 40,000 people) suffering from heart failure with a poor ejection fraction, which is also known as diastolic heart failure.

To date there has been no medical response or clinically proven treatments for them.

The study was double-blind and included 5,988 people dealing with heart failure.

Of these, 67% had a left ventricular emission segment (LVEF) of more than 50% and 33% had a LVEF between 40 and 50%.

The trial participants were randomly assigned to groups, who received the drug Gerdians or placebo once a day.

As mentioned, the results of the study showed a significant decrease in mortality and hospitalizations from heart failure among those who received the treatment, compared to those who received a placebo.

"I see people diagnosed with the disease and aware of the bleak reality that there are no clinically proven treatments I can offer them that will significantly affect their condition," said Professor Stefan Anker, lead researcher in the study and cardiologist specializing in heart failure at Scratch Hospital in Berlin, Germany. "These data are a source of hope for millions of people suffering from the disease. Study participants had varying levels of heart function, and only at least half of them had type 2 diabetes. 

Dr. Avishai Gruper, director of the cardiology department at Sheba Hospital and incoming chairman of the Cardiac Association's Department of Heart Failure, said: This type of heart failure is also very common in the country, and now for the first time there is a drug that has shown a significant reduction in the morbidity and mortality of this group of patients.The results emphasize the need to increase awareness of heart failure The progress and prevent complications. "